Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment

Jaclyn Beca, Don Husereau, Kelvin K.W. Chan, Neil Hawkins, Jeffrey S Hoch

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In evaluating new oncology medicines, two common modeling approaches are state transition (e.g., Markov and semi-Markov) and partitioned survival. Partitioned survival models have become more prominent in oncology health technology assessment processes in recent years. Our experience in conducting and evaluating models for economic evaluation has highlighted many important and practical pitfalls. As there is little guidance available on best practices for those who wish to conduct them, we provide guidance in the form of ‘Key steps for busy analysts,’ who may have very little time and require highly favorable results. Our guidance highlights the continued need for rigorous conduct and transparent reporting of economic evaluations regardless of the modeling approach taken, and the importance of modeling that better reflects reality, which includes better approaches to considering plausibility, estimating relative treatment effects, dealing with post-progression effects, and appropriate characterization of the uncertainty from modeling itself.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalPharmacoEconomics
DOIs
StateAccepted/In press - Nov 6 2017

Fingerprint

Biomedical Technology Assessment
Cost-Benefit Analysis
Practice Guidelines
Uncertainty

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment. / Beca, Jaclyn; Husereau, Don; Chan, Kelvin K.W.; Hawkins, Neil; Hoch, Jeffrey S.

In: PharmacoEconomics, 06.11.2017, p. 1-9.

Research output: Contribution to journalArticle

Beca, Jaclyn ; Husereau, Don ; Chan, Kelvin K.W. ; Hawkins, Neil ; Hoch, Jeffrey S. / Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment. In: PharmacoEconomics. 2017 ; pp. 1-9.
@article{d45c4bea278949598beee032739fb81d,
title = "Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment",
abstract = "In evaluating new oncology medicines, two common modeling approaches are state transition (e.g., Markov and semi-Markov) and partitioned survival. Partitioned survival models have become more prominent in oncology health technology assessment processes in recent years. Our experience in conducting and evaluating models for economic evaluation has highlighted many important and practical pitfalls. As there is little guidance available on best practices for those who wish to conduct them, we provide guidance in the form of ‘Key steps for busy analysts,’ who may have very little time and require highly favorable results. Our guidance highlights the continued need for rigorous conduct and transparent reporting of economic evaluations regardless of the modeling approach taken, and the importance of modeling that better reflects reality, which includes better approaches to considering plausibility, estimating relative treatment effects, dealing with post-progression effects, and appropriate characterization of the uncertainty from modeling itself.",
author = "Jaclyn Beca and Don Husereau and Chan, {Kelvin K.W.} and Neil Hawkins and Hoch, {Jeffrey S}",
year = "2017",
month = "11",
day = "6",
doi = "10.1007/s40273-017-0583-4",
language = "English (US)",
pages = "1--9",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment

AU - Beca, Jaclyn

AU - Husereau, Don

AU - Chan, Kelvin K.W.

AU - Hawkins, Neil

AU - Hoch, Jeffrey S

PY - 2017/11/6

Y1 - 2017/11/6

N2 - In evaluating new oncology medicines, two common modeling approaches are state transition (e.g., Markov and semi-Markov) and partitioned survival. Partitioned survival models have become more prominent in oncology health technology assessment processes in recent years. Our experience in conducting and evaluating models for economic evaluation has highlighted many important and practical pitfalls. As there is little guidance available on best practices for those who wish to conduct them, we provide guidance in the form of ‘Key steps for busy analysts,’ who may have very little time and require highly favorable results. Our guidance highlights the continued need for rigorous conduct and transparent reporting of economic evaluations regardless of the modeling approach taken, and the importance of modeling that better reflects reality, which includes better approaches to considering plausibility, estimating relative treatment effects, dealing with post-progression effects, and appropriate characterization of the uncertainty from modeling itself.

AB - In evaluating new oncology medicines, two common modeling approaches are state transition (e.g., Markov and semi-Markov) and partitioned survival. Partitioned survival models have become more prominent in oncology health technology assessment processes in recent years. Our experience in conducting and evaluating models for economic evaluation has highlighted many important and practical pitfalls. As there is little guidance available on best practices for those who wish to conduct them, we provide guidance in the form of ‘Key steps for busy analysts,’ who may have very little time and require highly favorable results. Our guidance highlights the continued need for rigorous conduct and transparent reporting of economic evaluations regardless of the modeling approach taken, and the importance of modeling that better reflects reality, which includes better approaches to considering plausibility, estimating relative treatment effects, dealing with post-progression effects, and appropriate characterization of the uncertainty from modeling itself.

UR - http://www.scopus.com/inward/record.url?scp=85033478497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033478497&partnerID=8YFLogxK

U2 - 10.1007/s40273-017-0583-4

DO - 10.1007/s40273-017-0583-4

M3 - Article

SP - 1

EP - 9

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

ER -